Study Summary
This study, a single-center, open, single-dose clinical study, was designed to evaluate the safety, tolerability, and pharmacokinetic profile of INS19 CAR-T cells for the treatment of patients with relapsed or refractory acute B lymphoblastic leukemia
Want to learn more about this trial?
Request More InfoInterventions
INS19 CAR-T CellsBIOLOGICAL
INS19 CAR-T Cells, 1-2×10\^7 cells, treatment follows a lymphodepletion. Drug: Fludarabine Recommendation: 25-30 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline. Drug: Cyclophosphamide Recommendation: 250-300 mg/m\^2/day (D-5\~D-3), determined by tumor burden at baseline.
Study Locations
No locations listed.